ASE · Analyst Forecast

Matinas Biopharma Holdings, Inc. (MTNB) Analyst Forecast

$1.70 ASE: MTNB Market Cap $726291

Revenue and earnings estimates published by analysts covering Matinas Biopharma Holdings, Inc. (MTNB), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Matinas Biopharma Holdings, Inc., analysts forecast revenue rising from $1.10T in 2023 to $120.09T in 2028; the average estimate for 2028 earnings per share is $165.00; 2 analysts contribute to these figures. These are forecasts published by analysts, not results.

Revenue forecast (USD millions)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

Year	Low	Average	High	Analysts
2023	$1.10T	$1.10T	$1.10T	2
2024	$500.0B	$500.0B	$500.0B	1
2025	$63.92T	$63.92T	$63.92T	1
2026	$93.32T	$93.32T	$93.32T	1
2027	$45.20T	$45.20T	$45.20T	1
2028	$120.09T	$120.09T	$120.09T	1

Earnings per share forecast

Year	Low	Average	High	Analysts
2023	$-5.50	$-5.50	$-5.50	2
2024	$-60.90	$-60.90	$-60.90	1
2025	$-22.50	$-22.50	$-22.50	1
2026	$-75.00	$-75.00	$-75.00	1
2027	$-37.50	$-37.50	$-37.50	1
2028	$165.00	$165.00	$165.00	1

Matinas Biopharma Holdings, Inc. (MTNB) forecast — frequently asked questions

What are analysts forecasting for Matinas Biopharma Holdings, Inc.'s earnings?

The average analyst estimate for Matinas Biopharma Holdings, Inc. (MTNB) earnings per share in 2028 is 165.00, with individual estimates between 165.00 and 165.00.

How much revenue is Matinas Biopharma Holdings, Inc. expected to make?

Analysts forecast Matinas Biopharma Holdings, Inc. (MTNB) revenue of $120.09T in 2028, based on 1 published estimates.

How many analysts cover MTNB?

2 analysts contribute estimates for Matinas Biopharma Holdings, Inc. (MTNB). Thin coverage makes an average less reliable.

Related stock screens

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks High ROE Stocks Low P/E Stocks High Net Margin Stocks Dividend Stocks Low Debt Stocks All stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.